SGN-15 (cBR96-doxorubicin immunoconjugate)

DRUG2 trials

Sponsors

Seagen Inc.

Conditions

Ovarian NeoplasmsProstatic Neoplasms

Phase 2

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

CompletedNCT00031187

Seagen Inc.Prostatic Neoplasms

Start: 2000-10-31End: 2003-07-31Target: 160Updated: 2011-10-24

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

TerminatedNCT00051584

Seagen Inc.Ovarian Neoplasms

End: 2003-05-31Target: 60Updated: 2011-10-24